Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotech company dedicated to developing arfolitixorin, a next-generation folate-based drug candidate designed to enhance the efficacy of standard treatments for patients with severe cancer.
Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s shares are traded on Nasdaq Stockholm.
Latest press releases
2026-02-03
Silver Brand Talks
Isofol’s CEO, Petter Segelman Lindqvist, has been interviewed in the podcast Silver Brand Talks, where they talk about branding and design in biotechnology and more specifically about Isofol’s brand change.
2026-01-21
Redeye Fight Cancer 2026
Isofol attended Redeye Theme Event Fight Cancer and CEO, Petter Segelman Lindqvist, gave an updated on the company and the ongoing clinical phase Ib-study.
2025-11-14
Interview with Charité – Universitätsmedizin Berlin
Watch the interview with Prof. Sebastian Stintzing who is the principal coordinating investigator in Isofol’s on-going phase Ib/II study.
For investors
Upcoming Events
- February 18, 2026 - February 18, 2026
Year-end report 2025 - March 10, 2026 - March 11, 2026
Stora Aktiedagarna
Isofol is participating in the Aktiespararna's event on March 10 in Stockholm and will present the company at 16:25 CET. - May 19, 2026 - May 19, 2026
Interim Report January-March 2026
Latest reports and presentations
